The INTENSIFY study: practical daily effectiveness and tolerance of ivabradine in chronic systolic heart failure in Germany Zugck C, Martinka P, Stöckl.

Slides:

Advertisements

Similar presentations

patients, 51 countries, 1139 centers Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Rationale, design, and baseline characteristics of.

Advertisements

EP Testing and Use of Devices in Heart Failure HFSA 2010 Recommendations.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with chronic systolic heart failure.

Diuretic Strategies in Patients with Acute Decompensated Heart Failure Diuretic Optimization Strategies Evaluation (DOSE) trial.

Discussant Inder Anand, MD, FRCP, D Phil (Oxon.)

Purpose To determine whether metoprolol controlled/extended release

Overcoming the challenge of blood pressure control in prediabetic and diabetic patients: PICASSO T2D Study Efficacy and tolerability of fixed dose combination.

Improving survival in symptomatic ischemic patients with left ventricular dysfunction Beneficial effects of long-term trimetazidine* therapy Fragasso G.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Heart rate reduction with ivabradine and health related quality of life in.

analysis from the SHIFT study

Corlanor® - Ivabradine

Preliminary results from the C-Pulse OPTIONS HF European Multicenter Post-Market Study Holger Hotz, CardioCentrum Berlin, Berlin, Germany; Antonia Schulz,

Procoralan plus beta-blockers as first-step therapy in heart failure?

May 23rd, 2012 Hot topics from the Heart Failure Congress in Belgrade.

Cardiac Arrhythmias in Coronary Heart Disease SIGN 94.

JONATHAN MANT, MD; ABDALLAH AL-MOHAMMAD, MD; SHARON SWAIN, BA, PHD; AND PHILIPPE LARAMEE,DC,MSC, FOR THE GUIDELINE DEVELOPMENT GROUP CHRIS FONTIMAYOR MS-III.

CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

Clinical Impact of Adherence to Pharmacotherapeutic Guidelines on the Outcome in Patients with Chronic Heart Failure Suntheep Batra, M.Pharm Department.

Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.

Effect of ivabradine on recurrent hospitalization for worsening heart failure: findings from SHIFT S ystolic H eart failure treatment with the I f inhibitor.

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

European guidelines on the management of stable coronary artery disease Key points & new position for Ivabradine and Trimetazidine ESC 2013 Montalescot.

Evidence-based Checkup for Patient Education Web Sites Suzanne Austin Boren, MHA Center for Health Care Quality University of Missouri

1 EFFECT STUDY 2 EFFECT STUDY  Set national cardiac care benchmarks for hospitals to work towards 

Effect of ivabradine on recurrent hospitalization for worsening heart failure: findings from SHIFT S ystolic H eart failure treatment with the I f inhibitor.

Target Study Cardiac resynchronization therapy (CRT) is an established treatment for advanced heart failure symptoms, impaired LV systolic function, and.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results Swedberg K, et al. Lancet. 2010;376(9744):

To know more visit HeartFailure.com © 2015 Novartis Pharma AG, May 2015, GLCM/HTF/0028 HEART FAILURE DISEASE MANAGEMENT STANDARDS.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with severe chronic systolic.

AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.

BEST: Beta-blocker Evaluation Survival Trial Purpose To determine whether the β-blocker bucindolol reduces morbidity and mortality in patients with advanced.

The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT Systolic Heart failure.

Circulating Long-Chain ω-3 Fatty Acids and Incidence of Congestive Heart Failure in Older Adults: The Cardiovascular Health Study Funded by: National Institutes.

SMMART-HF Surgery vs. Medical Treatment Alone for Patients with Significant MitrAl RegurgitaTion & Non-Ischemic Congestive Heart Failure Duke Heart Failure.

Camm J, et al. On Behalf of The SHIFT Gothenburg, Cardiac safety of selective heart rate reduction with Ivabradine in chronic heart failure. Poster, Heart.

The Studies of Oral Enoximone Therapy in Advanced Heart Failure ESSENTIALESSENTIAL Presented at The European Society of Cardiology Congress 2005 Presented.

Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure Systolic Heart.

ACCP Cardiology PRN Journal Club

Columbia University Medical Center The Cardiovascular Research Foundation Temporal Improvement in Carotid Stent Outcomes: Achievement of AHA Target Goals.

News You Can Use… Josh Stewart, PharmD Candidate 2016 Pete Koval, PharmD Cone Health Family Medicine October 2015.

COMET: Carvedilol Or Metoprolol European Trial Purpose To compare the effects of carvedilol (a β 1 -, β 2 - and α 1 -receptor blocker) and short-acting.

Heart rate in heart failure: Heart rate in heart failure: risk marker or risk factor? A subanalysis of the SHIFT trial on behalf of the Investigators M.

BACKGROUND Refractory angina The balloon expandable, stainless steel, hourglass-shaped, coronary-sinus reducing device creates a focal narrowing and increases.

CR-1 Candesartan in HF Benefit/Risk James B. Young, MD Cleveland Clinic Foundation.

New 2011 SHIFT quality of life substudy Quality of life ( QoL) in heart failure: where do we stand? Therapies that have survival benefits either have a.

COPERNICUS: Carvedilol Prospective Randomized Cumulative Survival trial Purpose To assess the effect of carvedilol, a β 1 -, β 2 - and α 1 -receptor blocker,

The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.

Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients with Heart Failure with preserved Ejection Fraction Effect of Spironolactone.

Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.

Efficacy of Colchicine When Added to Traditional Anti- Inflammatory Therapy in the Treatment of Pericarditis Efficacy of Colchicine When Added to Traditional.

DIAGNOSIS No symptoms = no heart failure. DIAGNOSIS No symptoms = no heart failure.

– р<0.05 between baseline

Clinical outcomes among patients with chronic low back pain treated with pregabaline monotherapy in fort portal regional referral hospital, “case series”

JOURNAL REVIEW HEART FAILURE MANAGEMENT – BETA BLOCKERS

Ivabradine – A new option for Heart Failure Patients

EMPHASIS-HF Extended Follow-up

A Paradigm Shift in PAH.

Cardiovacular Research Technologies

Heart Rate, HF Admissions, and Readmissions

Jeff Macemon Waikato Cardiothoracic Unit

The following slides highlight a presentation at the Late-Breaking Clinical Trials session of the American Heart Association Scientific Sessions, November.

Section III: Neurohormonal strategies in heart failure

Systolic Heart failure treatment with the If inhibitor ivabradine Trial The effect of heart rate reduction with ivabradine on renal function in patients.

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Using Heart Rate as a Biomarker in Clinical Practice.

Section III: Neurohormonal strategies in heart failure

Case #1 Case #1 (cont) Case #1 (cont)

Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effect of ivabradine on recurrent hospitalization for worsening heart failure:

Presentation transcript:

The INTENSIFY study: practical daily effectiveness and tolerance of ivabradine in chronic systolic heart failure in Germany Zugck C, Martinka P, Stöckl G. Zugck C, Martinka P, Stöckl G. Ivabradine treatment in a chronic heart failure patient cohort: symptom reduction and improvement in quality of life in clinical practice. Adv Ther. 2014;31:961-974.

BACKGROUND Heart failure is a major problem both in terms of impact on patients’ daily lives and the cost to society, mainly due to the heavy burden of recurrent hospitalizations. The SHIFT study has shown that ivabradine improves cardiovascular outcomes in a wide range of chronic heart failure (CHF) patients. This risk reduction was achieved on top of background pharmacotherapy, including beta-blockers, and led to the recommendation of ivabradine in heart failure guidelines. The INTENSIFY study analyzed the effectiveness of ivabradine in reducing symptoms and improving quality of life, and in terms of tolerability, in CHF patients in daily clinical practice over a 4-month period. The INTENSIFY study can be likened to the SHIFT study translated into clinical practice. Zugck C, Martinka P, Stöckl G. Ivabradine treatment in a chronic heart failure patient cohort: symptom reduction and improvement in quality of life in clinical practice. Adv Ther. 2014;31:961-974.

METHODOLOGY The INTENSIFY study is a prospective, non-interventional, open-label multicenter study conducted in 694 centers in Germany. 1956 patients enrolled have chronic systolic heart failure (origin of heart failure: ischemic in 62.4%, nonischemic in 31.7%, and both in 5.8%), fulfilling criteria for treatment with ivabradine according to the approved indication (sinus rhythm, NYHA class II–IV, resting heart rate 70/75 bpm). The INTENSIFY study evaluated the effectiveness, tolerability, and effect on quality of life of ivabradine over a 4-month period. The effectiveness of ivabradine was assessed in addition to standard heart failure treatment. The study was conducted by cardiologists, specialized general practitioners, and internists, and thus reflects daily clinical practice. Zugck C, Martinka P, Stöckl G. Ivabradine treatment in a chronic heart failure patient cohort: symptom reduction and improvement in quality of life in clinical practice. Adv Ther. 2014;31:961-974.

Ivabradine rapidly improves symptoms RESULTS Ivabradine rapidly improves symptoms Zugck C, Martinka P, Stöckl G. Ivabradine treatment in a chronic heart failure patient cohort: symptom reduction and improvement in quality of life in clinical practice. Adv Ther. 2014;31:961-974.

Ivabradine rapidly improves quality of life RESULTS Ivabradine rapidly improves quality of life Zugck C, Martinka P, Stöckl G. Ivabradine treatment in a chronic heart failure patient cohort: symptom reduction and improvement in quality of life in clinical practice. Adv Ther. 2014;31:961-974.

IMPACT ON CLINICAL PRACTICE The INTENSIFY study has shown that there is room for further symptomatic improvement in chronic heart failure patients, despite current treatments such as beta-blockers. Ivabradine has proven in clinical practice to be rapidly effective in reducing symptoms of heart failure, and improving quality of life in chronic heart failure patients. Zugck C, Martinka P, Stöckl G. Ivabradine treatment in a chronic heart failure patient cohort: symptom reduction and improvement in quality of life in clinical practice. Adv Ther. 2014;31:961-974.